Brain Tumor Group

Research Groups

Restricted acces

Structure

Chair

Michael Weller
UniversitaetsSpital Zurich
Zurich, Switzerland

Secretary

J.C. Reijneveld
Vrije Universiteit Medisch Centrum
Amsterdam, The Netherlands

Treasurer

Frederic Dhermain
Institut Gustave Roussy
Villejuif, France

Steering Committee

M. Weller, UniversitaetsSpital Zurich, Zurich (CH)
J.C. Reijneveld, Vrije Universiteit Medisch Centrum, Amsterdam (NL)
F. Dhermain, Institut Gustave Roussy, Villejuif (FR)
W. Wick, UniversitaetsKlinikum Heidelberg, Heidelberg (DE)
A. Brandes, Ospedale Bellaria, Bologna (IT)
B. Baumert, MediClin Robert Janker Klinik, Bonn (DE)
M. Bendszus, UniversitaetsKlinikum Heidelberg, Heidelberg (DE)
M. Van den Bent, ErasmusMC, Rotterdam (NL)
M. Preusser, Medical University Vienna, Vienna (AT)
M. Kros, ErasmusMC, Rotterdam (NL)
M. Hegi, Centre Hospitalier Universitaire Vaudois, Lausanne (CH)
P. Hau, Universitaetskliniken Regensburg, Regensburg (DE)
R. Soffietti, Azienda Ospedaliera Città della Salute e della Scienza di Torino – Ospedale San Giovanni, Torino (IT)
E. Le Rhun, CHRU de Lille, Lille (FR)
P. French, ErasmusMC, Rotterdam (NL)

Committees Chairs

Translational Research and Pathology

Chair: M. Kros, Rotterdam (NL)

The EORTC BTG Translational Research Committee reviews all translational research projects of the EORTC BTG. This includes translational research as part of clinical BTG protocols and post-hoc research proposals. It provides feedback on the projects and provides guidance on the best experimental techniques and helps to prioritize the use of patient material to achieve the scientific goals. It will provide suggestions for prioritization within the BTG budget in case funds from the group are required to conduct the project. Participating in the committee and reviewing proposals neither justifies a request for authorship, nor does it exclude this.

Pathology & Translational Research committee
Anna Berghoff, Medical University Vienna – General Hospital AKH, Vienna (AT)
Guido Reifenberger, Universitaetsklinik Düsseldorf, Düsseldorf (DE)
Sebastian Brandner, National Hospital for Neurology and Neurosurgery, London (UK)
Adelheid Wöhrer, Medical University Vienna, Vienna (AT)
Franck Bielle, Salpetrière, Paris (FR)
Christian Mawrin, Otto von Guericke Universität, Magdeburg (DE)

Quality Assurance

Chair: P. Hau, Regensburg (DE)

The mission of the EORTC BTG Quality Assurance (QA) Committee is to prepare quality standards for BTG-related activities and to ensure that BTG activity is performed within these standards.
Quality assurance processes include interactions of the BTG with the EORTC Headquarters, the development of standard operating procedures for the BTG including measurement of key indicators of BTG performance, and the evaluation of BTG affiliated centers including basic quality standards for neurosurgery, radiation oncology, medical oncology or neuro-oncology, neuropathology, neuroimaging, diagnostics, symptom control, adherence to guidelines, and documentation. Radiation oncology standards are maintained in strong collaboration with the radiation oncology group (ROG) and the QART committee within the headquarters (HQ). A set of standards involving patient numbers, infrastructure and level of service agreements to facilitate trial participation are defined in close collaboration with the HQ individually for each trial. In addition, the QA committee aims to develop scientific projects that are related to QA questions.
We believe that continuous quality improvement is the foundation for excellence within the BTG. To achieve this goal, the QA committee will develop a “Quality Management System“ that, through a regular auditing process, ensures that all QA-attached processes are strictly adhered to.

Quality Assurance committee
Frederic Dhermain, Institut Gustave Roussy, Paris (FR)
Filip de Vos, UMC Utrecht, Utrecht (NL)
Nicolaus Andratschke, USZ, Zürich (CH)
Evangelia Razis, Hygeia Hospital, Athens (GR)
Colin Watts, Cambridge University Hospital NHS – Addenbrookes Hospital, Cambridge (UK)
Brigitta Baumert, MediClin Robert Janker Klinik, Bonn (DE)

Quality of Life

Chair: J. Reijneveld, Amsterdam (NL)

The Quality of Life (QOL) Committee of the EORTC Brain Tumour Group coordinates all QOL-related issues of the Brain Tumour Group. The main tasks of the committee are 1) to advise on the implementation of QOL measurement (e.g. timing, frequency, tools, primary analysis) in new trials initiated by the group, 2) to monitor QOL data collection and primary analysis of this outcome measure in all running trials, 3) to perform additional analysis on the collected QOL data of single or combined datasets of those clinical trials, and 4) to develop and or update QOL measurement instruments whenever necessary. The QOL Committee will coordinate these tasks, set priorities in terms of timelines and financial support, and if necessary apply for additional funding. All these tasks will be performed in close collaboration with the EORTC Quality of Life Department, the EORTC Quality of Life Group, and the principal investigators of the respective trials. Participating in the committee neither justifies a request for authorship, nor does it exclude this.

Quality of Life committee
Claudia Panciroli, University Hospital Germans Trias i Pujol – Catalan Institute of Oncology, Badalona (Barcelona, ES)
Andrew Bottomley, EORTC, Brussels (BE)
Corneel Coens, EORTC, Brussels (BE)
Linda Dirven, Leiden UMC, Leiden (NL)
Emilie Le Rhun, CHRU de Lille, Lille (FR)
Clemens Seidel, University Hospital Leipzig, Leipzig (DE)
Christina Marosi, Medical University of Vienna, Vienna (AT)
Martin Taphoorn, MC Haaglanden, The Hague (NL)

Imaging

Chair: M. Bendszus, Heidelberg (DE)

The imaging committee within the BTG aims at establishing an imaging infrastructure for clinical brain tumor trials. This includes development of protocols, advising on the IT infrastructure and performing QC and central review. Imaging data of clinical trials will also be used for secondary analyses with a focus on imaging-specific research questions. The second aim of the committee is to move forward translational imaging research, in particular developing techniques and protocols which can be used in clinical trials in the near future. Moreover the members of the committee will be involved in validating and optimizing imaging endpoints for clinical trials in adjunct to clinical and other paraclinical parameters. The committee is strongly liaised with the imaging group of the EORTC.

Imaging committee
Marion Smits, ErasmusMC, Rotterdam (NL)
Julia Furtner, Medical University of Vienna, Vienna (AT)
Enrico Franceschi , Bellaria Maggiori Hospital, Bologna (IT)
Frederic Dhermain, Gustave Roussy, Paris (FR)
Norbert Galldiks, Universitaetsklinikum Köln, Köln (DE)
Slavka Lukacova, Aarhus University Hospital, Aarhus (DK)
Nils Ole Schmidt, Hamburg-Eppendorf Medical Center, Hamburg (DE)
Damien Galanaud, Pitié-Salpetrière, Paris (FR)
Philipp Kickingereder, UniversitaetsKlinikum Heidelberg, Heidelberg (DE)

SPECTA

Chair: M. Hegi, Lausanne (CH)

The SPECTA committee oversees the integration of the SPECTA infrastructure in the BTG clinical and translational research activities.

SPECTA committee
Matthias Preusser, Medical University of Vienna, Vienna (AT)
Mathilde Kouwenhoven, VU University Medical Center, Amsterdam (NL)
Patrick Roth, University Hospital Zürich, Zürich (CH)
Gaetano Finocchiaro, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan (IT)
Pim French, ErasmusMC, Rotterdam (NL)
Marc Sanson, Hopital Salpetrière, Paris (FR)

Meningioma

Chair: M. Preusser, Vienna (AT)

The goal of the Meningioma Committee is to initiate and coordinate clinical trial initiatives on meningiomas within the EORTC BTG. A strong focus is on incorporation of translational research projects in the context of clinical trial activities. The Committee is composed of multidisciplinary and multinational specialists with a special interest in meningioma research. The Meningioma Committee works closely with the Translational Research and Pathology Committee, the Quality Assurance Committee, the Quality of Life Committee, the Imaging Committee and the SPECTA Committee and is also in close contact with other international research groups working on meningioma to facilitate collaboration whenever feasible.

Meningioma committee
Christian Mawrin, Otto von Guericke Universität, Magdeburg (DE)
Emilie Le Rhun, CHRU de Lille, Lille (FR)
Felix Sahm, UniversitaetsKlinikum Heidelberg, Heidelberg, (DE)
Giuseppe Minniti, Universita Degli Studi Di Roma La Sapienza, Rome (IT)
Julia Furtner, Medical University Vienna, Vienna (AT)
Roland Goldbrunner, Universitaetsklinikum Köln, Cologne (DE)

CNS metastasis

Chair: E. Le Rhun, Lille (FR)

The CNS Metastasis Committee orchestrates experimental and clinical research activities within the EORTC Brain Tumor Group. Scientific projects focus on the pathogenesis of brain metastasis from solid tumors. Clinical projects encompass neuroimaging approaches and CSF studies, specifically with regards to response assessment. The committee seeks to develop clinical trial protocols exploring new agents in cooperation with other EORTC groups as well as with clinical research networks and cooperative groups outside EORTC.

CNS metastasis committee
Frederic Dhermain, Gustave Roussy, Paris (FR)
Pieter Wesseling, Radboud University Medical Center Nijmegen, Nijmegen (NL)
Martin Bendzus, UniversitaetsKlinikum Heidelberg, Heidelberg (DE)
Joerg-Christian Tonn, Klinikum der Universitaet Muenchen, Munich (DE)
Frank Winkler, UniversitaetsKlinikum Heidelberg, Heidelberg (DE)
Matthias Preusser, Medical University of Vienna, Vienna (AT)
Riccardo Soffietti, Ospedale San Giovanni, Torino (IT)

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200
Belgium

Contact us

Follow us

Funding